Antengene announces xpovio® approved for public health insurance coverage in taiwan market, benefiting more patients with r/r mm in the region

Xpovio® is the first xpo1 inhibitor approved in taiwan for the treatment of adult patients with relapsed/refractory multiple myeloma (r/r mm). after the mainland of china, south korea, australia and singapore, taiwan market is the fifth apac market in which xpovio® has been approved for public health insurance coverage.
KPTI Ratings Summary
KPTI Quant Ranking